Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Charles Geyer"'
Autor:
Joseph Sparano, Robert J. Gray, Della Makower, Kathy S. Albain, Daniel F. Hayes, Charles Geyer, Elizabeth Dees, Matthew P. Goetz, John A. Olson, Tracy G. Lively, Sunil Badve, Thomas Saphner, Lynne I. Wagner, Timothy Whelan, Virginia Kaklamani, George Sledge
Publikováno v:
Cancer Research. 83:GS1-05
Background: Late recurrence of breast cancer after 5 years accounts for about 50% of recurrences in hormone receptor (HR)-positive early breast cancer (EBC). TAILORx established non-inferiority of adjuvant endocrine therapy (ET) given for at least 5
Autor:
Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer, Andrew Tutt
Publikováno v:
Breast Cancer.
Background The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and contextualized with reference to the global OlympiA population. Methods Patient
Autor:
José Baselga, Neal Rosen, Joaquin Arribas, David Cameron, Charles Geyer, Henry Gomez, Maria Koehler, Robert Gagnon, Catherine Ellis, Josep Lluis Parra, Marta Guzman, Gertrudis Sánchez, Pier Davide Angelini, José Jimenez, Claudia Aura, Ludmila Prudkin, Sarat Chandarlapaty, Maurizio Scaltriti
Supplementary Data from Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ab4055c3c0afbef48f7ad680292f73
https://doi.org/10.1158/1078-0432.22442855.v1
https://doi.org/10.1158/1078-0432.22442855.v1
Autor:
José Baselga, Neal Rosen, Joaquin Arribas, David Cameron, Charles Geyer, Henry Gomez, Maria Koehler, Robert Gagnon, Catherine Ellis, Josep Lluis Parra, Marta Guzman, Gertrudis Sánchez, Pier Davide Angelini, José Jimenez, Claudia Aura, Ludmila Prudkin, Sarat Chandarlapaty, Maurizio Scaltriti
Purpose: A subgroup of human epidermal growth factor receptor 2 (HER2)–overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a837f5e32a513948c40bba407b6363d6
https://doi.org/10.1158/1078-0432.c.6519506
https://doi.org/10.1158/1078-0432.c.6519506
Autor:
Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert Hills, Zulian Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno-Aspitia, Martine Piccart, Michael Press, Edward Romond, Dennis Slamon, Vera Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles Geyer, Marc Spielmann, Pinuccia Valagussa, Kathy Albain, Rodrigo Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith Bliss, Etienne Brain, Lisa Carey, Robert Coleman, Jack Cuzick, Nancy Davidson, Lucia Del Mastro, Angelo Di Leo, James Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith Regan, John Robertson, Emiel Rutgers, Tanja Spanic, Joseph Sparano, Guenther Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Tim Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I Pritchard, Sandra M Swain
Publikováno v:
The Lancet. Oncology
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6
Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxic
Autor:
Richard Gray, Rosie Bradley, Jeremy Braybrooke, Zulian Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, William Barlow, Judith Bliss, Paolo Bruzzi, David Cameron, George Fountzilas, Sibylle Loibl, John Mackey, Miguel Martin, Lucia Del Mastro, Volker Möbus, Valentina Nekljudova, Sabino De Placido, Sandra Swain, Michael Untch, Kathleen I Pritchard, Jonas Bergh, Larry Norton, Clare Boddington, Julie Burrett, Mike Clarke, Christina Davies, Fran Duane, Vaughan Evans, Lucy Gettins, Jon Godwin, Robert Hills, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Yaochen Wang, Zhe Wang, Peter Fasching, Nadia Harbeck, Pascal Piedbois, Michael Gnant, Guenther Steger, Angelo Di Leo, Stella Dolci, Prue Francis, Denis Larsimont, Jean Marie Nogaret, Catherine Philippson, Martine Piccart, Sabine Linn, Petronella Peer, Vivianne Tjan-Heijnen, Sonja Vliek, Dennis Slamon, John Bartlett, Vivien H Bramwell, Bingshu Chen, Stephen Chia, Karen Gelmon, Paul Goss, Mark Levine, Wendy Parulekar, Joseph Pater, Eileen Rakovitch, Lois Shepherd, Dongsheng Tu, Tim Whelan, Don Berry, Gloria Broadwater, Constance Cirrincione, Hyman Muss, Raymond Weiss, Yi Shan, Yong Fu Shao, Xiang Wang, Binghe Xu, Dong-Bing Zhao, Harry Bartelink, Nina Bijker, Jan Bogaerts, Fatima Cardoso, Tanja Cufer, Jean-Pierre Julien, Philip Poortmans, Emiel Rutgers, Cornelis van de Velde, Eva Carrasco, Miguel Angel Segui, Jens Uwe Blohmer, Serban Costa, Bernd Gerber, Christian Jackisch, Gunter von Minckwitz, Mario Giuliano, Michele De Laurentiis, Christina Bamia, Georgia-Angeliki Koliou, Dimitris Mavroudis, Roger A'Hern, Paul Ellis, Lucy Kilburn, James Morden, John Yarnold, Mohammad Sadoon, Augustinus H Tulusan, Stewart Anderson, Gordon Bass, Joe Costantino, James Dignam, Bernard Fisher, Charles Geyer, Eleftherios P Mamounas, Soon Paik, Carol Redmond, D Lawrence Wickerham, Marco Venturini, Claudia Bighin, Simona Pastorino, Paolo Pronzato, Mario Roberto Sertoli, Theodorus Foukakis, Kathy Albain, Rodrigo Arriagada, Elizabeth Bergsten Nordström, Francesco Boccardo, Etienne Brain, Lisa Carey, Alan Coates, Robert Coleman, Candace Correa, Jack Cuzick, Nancy Davidson, Mitch Dowsett, Marianne Ewertz, John Forbes, Richard Gelber, Aron Goldhirsch, Pamela Goodwin, Daniel Hayes, Catherine Hill, James Ingle, Reshma Jagsi, Wolfgang Janni, Hirofumi Mukai, Yasuo Ohashi, Lori Pierce, Vinod Raina, Peter Ravdin, Daniel Rea, Meredith Regan, John Robertson, Joseph Sparano, Andrew Tutt, Giuseppe Viale, Nicholas Wilcken, Norman Wolmark, Wiliam Wood, Milvia Zambetti
Publikováno v:
The Lancet, vol. 393, no. 10179, pp. 1440-1452, 2019.
Cameron, D 2019, ' Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials ', The Lancet . https://doi.org/10.1016/S0140-6736(18)33137-4
Cameron, D 2019, ' Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials ', The Lancet . https://doi.org/10.1016/S0140-6736(18)33137-4
Background Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. Method
Autor:
Antonietta Mira, Charles Geyer
Publikováno v:
Monte Carlo Methods. :95-110
Autor:
Charles Geyer
Publikováno v:
Chapman & Hall/CRC Handbooks of Modern Statistical Methods ISBN: 9781420079418
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c14934d10df65e6e72832ba6adbae716
https://doi.org/10.1201/b10905-2
https://doi.org/10.1201/b10905-2
Autor:
Robert De Jager, E C E Charles Geyer, Thomas R. Johnson, Jinee Rizzo, Gail G. Eckhardt, Lisa A. Hammond, Ronald Drengler, Anthony W. Tolcher, Daniel D. Von Hoff, Garry Schwartz, Leslie Smetzer, Eric K. Rowinsky, John Coyle
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(17)
PURPOSE: To assess the feasibility of administering DX-8951f (exatecan mesylate), a water-soluble, camptothecin analog, as a 30-minute intravenous infusion daily for 5 days every 3 weeks, determine the maximum-tolerated dose (MTD) and pharmacokinetic
Publikováno v:
Evolution. 57:686